Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

TofuGlitch_39 Nov. 14 at 5:15 PM

$PBM I’m focused on NXXT because earnings may be today and at $2 the multiple is still compressed so I want the upside from normalization with PT $5–6 average $5.50 backed by BlackRock 582,422 ≈ $1.16M and Geode ~314,454 ≈ $0.63M

0 · Reply

Love_To_Learn Nov. 14 at 1:47 PM

$GCTK $PBM $ENVB $BDRX $AIFU shift

0 · Reply

isaacwilliams33 Nov. 13 at 9:52 PM

$PBM bio

0 · Reply

Jbjb90 Nov. 13 at 6:35 PM

$PBM back to 3 💪

0 · Reply

Tradetime3472 Nov. 13 at 6:34 PM

$PBM Im hoping for some type of funding from Texas or Arizona for our ibogaine operations

0 · Reply

Klinsmann Nov. 13 at 4:04 PM

$PBM 👀

0 · Reply

Jbjb90 Nov. 13 at 3:13 PM

$PBM it wants to go

0 · Reply

Jbjb90 Nov. 12 at 12:51 PM

$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-establishes-ibogaine-operations-in-africa-through-mji5175wz5es.html

0 · Reply

Jbjb90 Nov. 12 at 12:49 PM

$PBM

0 · Reply

StocktwitsNews Nov. 12 at 12:44 PM

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs $PBM https://stocktwits.com/news/others/business/psyence-bio-med-establishes-ibogaine-operations-in-africa-through-strategic-investment-in-psy-labs/cLPIwrYRE5D

0 · Reply

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 8 days ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 11 days ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 5 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 5 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 5 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 5 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 6 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 7 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 7 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 7 months ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 7 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 7 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 8 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 8 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 9 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 11 months ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 11 months ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 11 months ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 11 months ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 18, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 9:31 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 6, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Jul 26, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 3, 2024, 8:34 PM EDT - 1 year ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

May 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

TofuGlitch_39 Nov. 14 at 5:15 PM

0 · Reply

Love_To_Learn Nov. 14 at 1:47 PM

$GCTK $PBM $ENVB $BDRX $AIFU shift

0 · Reply

isaacwilliams33 Nov. 13 at 9:52 PM

$PBM bio

0 · Reply

Jbjb90 Nov. 13 at 6:35 PM

$PBM back to 3 💪

0 · Reply

Tradetime3472 Nov. 13 at 6:34 PM

$PBM Im hoping for some type of funding from Texas or Arizona for our ibogaine operations

0 · Reply

Klinsmann Nov. 13 at 4:04 PM

$PBM 👀

0 · Reply

Jbjb90 Nov. 13 at 3:13 PM

$PBM it wants to go

0 · Reply

Jbjb90 Nov. 12 at 12:51 PM

$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-establishes-ibogaine-operations-in-africa-through-mji5175wz5es.html

0 · Reply

Jbjb90 Nov. 12 at 12:49 PM

$PBM

0 · Reply

StocktwitsNews Nov. 12 at 12:44 PM

0 · Reply

DARKP00L Nov. 12 at 12:26 PM

$PBM 07:12 on Nov. 12 2025 Psyence BioMed Expands Through PsyLabs, Establishing Exclusive Public Market Presence In Africa For Ibogaine & Psilocybin Development #tradeideas

0 · Reply

olivia_clark19 Nov. 12 at 11:43 AM

$PBM thin tape. If it prints trend day over ORH, scalp +12–18%. Hard stops mandatory.

0 · Reply

exile0002 Nov. 12 at 11:19 AM

$PBM $ADTX $SGBX $ENVB $UPC.X $ADTX one of most diluted stocks in entire market and it will not end !!!!!

0 · Reply

PaulLaurent Nov. 12 at 10:39 AM

📉🧾 Stocks with the Lowest Outstanding Shares 🧾📉 $PBM $ADTX $SGBX $ENVB $UPC.X

0 · Reply

PaulLaurent Nov. 12 at 10:37 AM

🪙📉 Lowest Market Cap Stocks 📉🪙 $MSPR $PBM $RUBI $QH $CHR.X

1 · Reply

Neggudgid Nov. 11 at 7:03 PM

$PBM Had to bail fellas. Dead money here. I’ll keep an eye on ya. Good luck

0 · Reply

Jbjb90 Nov. 10 at 11:36 PM

$PBM https://www.tipranks.com/news/company-announcements/psyence-biomed-advances-phase-iib-clinical-trial-and-expands-board

0 · Reply

Neggudgid Nov. 10 at 10:47 PM

$PBM Great news, but why release it AH? Try a 9:30 drop fellas!

0 · Reply

PaulLaurent Nov. 7 at 6:27 AM

🪙📉 Lowest Market Cap Stocks 📉🪙 $MSPR $PBM $RUBI $QH $AKAN

1 · Reply

encostock Nov. 6 at 3:09 PM

$PBM top line data delayed end 2026 fake

1 · Reply

MoneyorBagHolder Nov. 6 at 3:03 PM

$PBM Where is today’s volume? For a sec I thought my screen froze? Lol. I just saw another news on $PBM which has more details on thinkorswim. I see it as great news but with a volume less than 43K this stock seems not to be moving.

0 · Reply

Market Cap	4.76M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,200
Avg Vol	728,550
Day's Range	N/A - N/A
Shares Out	1.87M
Stochastic %K	62%
Beta	0.25
Analysts	Strong Buy
Price Target	N/A